Cite
APA Citation
Raab, M. S., Engelhardt, M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Ferstl, B., Schub, N., Röllig, C., Weisel, K., Winderlich, M., Griese, J., Härtle, S., Weirather, J., Jarutat, T., Peschel, C., & Chatterjee, M. (2020). mOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial. Lancet, 7(5), e381–e394. http://access.bl.uk/ark:/81055/vdc_100104133546.0x000006